Literature DB >> 32277286

Comparative bioinformatical analysis of pancreatic head cancer and pancreatic body/tail cancer.

Lingdi Yin1,2, Linmei Xiao3, Yong Gao1,2, Guangfu Wang1,2, Hao Gao1,2, Yunpeng Peng1,2, Xiaole Zhu1,2, Jishu Wei1,2, Yi Miao4,5, Kuirong Jiang6,7, Zipeng Lu8,9.   

Abstract

This study is to analyze differentially expressed genes (DEGs) and mutation signatures of pancreatic head cancer and pancreatic body/tail cancer. Pancreatic Adenocarcinoma (PAAD) RNA-seq data, mutation data and clinical data were downloaded and collected from The Cancer Genome Atlas (TCGA), FireHose and CBioPortal. According to the anatomic location, the patients were divided into 146 cases of pancreatic head cancer and 28 cases of pancreatic body/tail cancer. Then survival analysis was performed by Kaplan-Meier and log-rank test. Furthermore, DEGs were screened by R package Deseq2. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction (PPI) were then carried out by DAVID and String. Online tool TIMER was used to analyze the immune cells infiltration. R package maftools and GenVisR were applied to analyze frequently mutated genes and mutant-allele tumor heterogeneity (MATH) of PAAD. Survival of patients with pancreatic body/tail cancer was better than those with pancreatic head cancer (median survival, 24.05 vs 19.45 months, p = 0.048). And 496 significant DEGs (|log2 FoldChange| > 1.5,false discovery rate (FDR) < 0.05) were identified, including 253 downregulated genes and 243 upregulated genes. And there were 13 Go terms (4 biological processes, 6 cellular components and 3 molecular functions) and 3 KEGG pathways (Pancreatic secretion, Fat digestion and absorption, Protein digestion and absorption) (FDR < 0.05). B cells and CD4 + T cells infiltration were more significant in pancreatic head cancer. MATH scores of pancreatic body/tail cancer were higher than pancreatic head cancer, while χ2 test of top 10 frequently mutated genes showed little difference between them. There were prognostic and genetic differences between pancreatic head cancer and pancreatic body/tail cancer. PAAD originated from different location may have different biology natures and should not be treated with same strategy.

Entities:  

Keywords:  Bioinformatics; Pancreatic body/tail cancer; Pancreatic head cancer

Year:  2020        PMID: 32277286     DOI: 10.1007/s12032-020-01370-0

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  30 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 2.  Prognostic factors related with survival in patients with pancreatic adenocarcinoma.

Authors:  Ahmet Bilici
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 3.  Vagaries of clinical presentation of pancreatic and biliary tract cancer.

Authors:  I Modolell; L Guarner; J R Malagelada
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

4.  The anatomic location of pancreatic cancer is a prognostic factor for survival.

Authors:  Avo Artinyan; Perry A Soriano; Christina Prendergast; Tracey Low; Joshua D I Ellenhorn; Joseph Kim
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

5.  Chemokine receptor CCR7 expression correlates with lymph node metastasis in pancreatic cancer.

Authors:  Bunzo Nakata; Shinya Fukunaga; Eiji Noda; Ryosuke Amano; Nobuya Yamada; Kosei Hirakawa
Journal:  Oncology       Date:  2008-06-11       Impact factor: 2.935

Review 6.  The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models.

Authors:  Qi Ling; Xiao Xu; Shu-Sen Zheng; Holger Kalthoff
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2013-10

Review 7.  Pancreatic cancer.

Authors:  Terumi Kamisawa; Laura D Wood; Takao Itoi; Kyoichi Takaori
Journal:  Lancet       Date:  2016-01-30       Impact factor: 79.321

8.  Statistical Approaches for the Construction and Interpretation of Human Protein-Protein Interaction Network.

Authors:  Yang Hu; Ying Zhang; Jun Ren; Yadong Wang; Zhenzhen Wang; Jun Zhang
Journal:  Biomed Res Int       Date:  2016-08-25       Impact factor: 3.411

9.  Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study.

Authors:  Fiona M Walter; Katie Mills; Silvia C Mendonça; Gary A Abel; Bristi Basu; Nick Carroll; Sue Ballard; John Lancaster; William Hamilton; Greg P Rubin; Jon D Emery
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-04

10.  CCL21/CCR7 Axis Contributed to CD133+ Pancreatic Cancer Stem-Like Cell Metastasis via EMT and Erk/NF-κB Pathway.

Authors:  Lirong Zhang; Dongqing Wang; Yumei Li; Yanfang Liu; Xiaodong Xie; Yingying Wu; Yuepeng Zhou; Jing Ren; Jianxin Zhang; Haitao Zhu; Zhaoliang Su
Journal:  PLoS One       Date:  2016-08-09       Impact factor: 3.240

View more
  8 in total

Review 1.  Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Andrew J McGuigan; Helen G Coleman; R Stephen McCain; Paul J Kelly; David I Johnston; Mark A Taylor; Richard C Turkington
Journal:  J Pathol Clin Res       Date:  2021-01-22

2.  Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer Locations.

Authors:  Ge Li; Cheng-Yu Liao; Jiang-Zhi Chen; Long Huang; Can Yang; Yi-Feng Tian; Yi-Ting Wang; Qiang Du; Qian Zhan; Yan-Ling Chen; Shi Chen
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

3.  CA9-Related Acidic Microenvironment Mediates CD8+ T Cell Related Immunosuppression in Pancreatic Cancer.

Authors:  Lingdi Yin; Yichao Lu; Cheng Cao; Zipeng Lu; Jishu Wei; Xiaole Zhu; Jianmin Chen; Feng Guo; Min Tu; Chunhua Xi; Kai Zhang; Junli Wu; Wentao Gao; Kuirong Jiang; Yi Miao; Qiang Li; Yunpeng Peng
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

4.  Comprehensive Analysis of Pyroptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Breast Cancer.

Authors:  JianBin Wu; Yuanyuan Zhu; MingMin Luo; Lei Li
Journal:  Front Immunol       Date:  2021-09-30       Impact factor: 7.561

5.  System Analysis of Adaptor-Related Protein Complex 1 Subunit Mu 2 (AP1M2) on Malignant Tumors: A Pan-Cancer Analysis.

Authors:  Yuanxue Yi; Qiufang Zhang; Youfeng Shen; Yueyi Gao; Xiaohong Fan; Sini Chen; Xin Ye; Jian Xu
Journal:  J Oncol       Date:  2022-02-10       Impact factor: 4.375

6.  A Pan-Cancer Analysis on the Systematic Correlation of MutS Homolog 2 (MSH2) to a Malignant Tumor.

Authors:  Hai Yao; Zhidong Cao; Haochuan Yong; Xiaoxing Zhang; Xin Zhang; Wei Li; Shenshen Zhi; Wenyan Wu
Journal:  J Oncol       Date:  2022-03-24       Impact factor: 4.375

7.  Long-term effects of total vs. partial pancreatectomy among patients with pancreatic cancer: a population-based study.

Authors:  Zhiwen Yang; Qiang Tao; Salamu Mijiti; Dandong Luo; Xiang Tang; Jia Liu; Lingmin Jiang; Zonghao Liu; Chen Liang; Xinyue Tu; Peng Zhao; Andreas Minh Luu; Francesco Serra; Roberta Gelmini; Yong Wang; Yun Zheng
Journal:  Ann Transl Med       Date:  2022-05

8.  Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer.

Authors:  Weiyu Ge; Jingyu Ma; Tiebo Mao; Haiyan Xu; Xiaofei Zhang; Shumin Li; Yongchao Wang; Jiayu Yao; Ming Yue; Feng Jiao; Yu Wang; Meng Zhuo; Ting Han; Jiong Hu; Xiao Zhang; Jiujie Cui; Liwei Wang
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.